1U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations[EB/OL].[2009- 06-10]. http://www, fda. gov/cder/ob/default. htm.
2Rockville L. Topical bioequivalence update. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Advisory Committee for Pharmaceutical Science Meeting[EB/OL. [2005- 02-04]. http://www, fda. gov/ohrms/dockets/ae/ 05/slides/2005 - 4137s2-Index. htm.
3U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320.1 (e), Of- fice of Federal Register. National Archives and Records Administration[S]. 2009.
4U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320.24, Office of Federal Register. National Archives and Records Administration[S]. 2009.
5U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Critical Path Op portunities for Generic Drugs[EB/OL]. [2007-05 01 ]. http://www, fda. gov/oc/initiatives/critical path/reports/generic, html.
6Office of Technology Assessment, Superintendent of Documents, U.S. Government Printing Office, Washington DC 20402. Drug Bioequivalence Study Panel. Drug bioequivalence[S]. 1974.
7U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320, Office of Federal Register. National Archives and Records Administration[S]. 2009.
8U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320. 22, Office of Federal Register. National Archives and Records Administration[S]. 2009.
9U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs, Division of Bioequivalence. Interim Guidance: Cholestyramine Powder - In Vitro Bioequivalence[EB/OL]. [ 1993-07]. http://www, fda. gov/ downloads/Drugs/GuidanceComplianceRegulatory-Information/ Guidances/ ucm070230. pdf.
10U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Immediate Release Solid Oral Dosage Forms. Scale Up and Post approval Changes: Chemistry, Manufac turing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation [ EB/ OL.] [1995-11]. http://www, fda. gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm070636. pdf.
